Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ) has announced the launch of its XPressMAX™ Cell-Free Protein Synthesis Kit (Cat#: CFKIT02), a new tool designed to accelerate AI-driven high-throughput screening for antibody drug discovery. The kit utilizes advanced cell-free protein synthesis technology to produce target proteins and antibodies in vitro, bypassing the constraints of traditional cell-based expression systems.
According to the company, the XPressMAX™ kit is based on an E. coli lysate fully supplemented with essential transcription and translation components, enabling direct protein synthesis from plasmid or PCR templates. Specifically engineered for antibody drug discovery, it supports rapid expression and validation of VHH, scFv, Fab, and miniproteins. Sino Biological has leveraged this technology to establish a high-throughput cell-free expression platform that validates over 2,000 scFv/VHH molecules in 3-4 weeks, matching the rapid iteration pace of AI.
Key highlights of the kit include ultra-fast synthesis completed in just 3 hours, a success rate greater than 99%, and support for complex disulfide bonding to achieve native folding and bioactivity without additional enhancers. “Our XPressMAX™ is a significant advancement in research tools and reagents for next-generation therapeutic discovery,” said Dr. Rob Burgess, Chief Business Officer at Sino Biological US, Inc. “By combining rapid, reliable protein expression with intelligent screening, we are helping our partners compress antibody discovery timelines without compromising quality.”
Dr. Jie Zhang, Sino Biological’s General Manager, added, “AI is revolutionizing antibody screening, but it demands expression systems that can match its speed and throughput. XPressMAX™ achieves rapid, high-success expression of challenging proteins in as little as 3 hours.” The kit integrates seamlessly with AI-powered screening platforms, empowering researchers to accelerate identification and optimization of promising antibody candidates while reducing development costs.
Researchers can visit Sino Biological's website to explore more about XPressMAX™ or request a free sample. The company also provides additional resources on its cell-free protein synthesis platform at this product page and solutions page.
Sino Biological is an international reagent supplier and CRO service provider specializing in recombinant protein production and antibody development. With US-based Center for Bioprocessing (C4B) in Houston and SignalChem Biotech in Canada, the company delivers tailored, localized solutions to researchers in over 90 countries. This launch marks a significant step in enabling faster, more efficient antibody drug discovery through the synergy of cell-free expression and AI.
